Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study

Psychometric Properties and Factor Structure of the Chinese Version of the Hospital Anxiety and Depression Scale in People Living With HIV

(2019) Zhiyuan Yang et al.   Frontiers in Psychiatry

HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz

(2018) Andrew Drury et al.   Malawi Medical Journal

Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs

(2018) Dhwanil A. Dalwadi et al.   PHARMACOLOGICAL REVIEWS

HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz

(2018) Andrew Drury et al.   Malawi Medical Journal

The Double Burdens of Mental Health Among AIDS Patients With Fully Successful Immune Restoration: A Cross-Sectional Study of Anxiety and Depression in China

(2018) Xiaojie Huang et al.   Frontiers in Psychiatry

Burden of sleep disturbances and associated risk factors: A cross-sectional survey among HIV-infected persons on antiretroviral therapy across China

(2017) Xiaojie Huang et al.   Scientific Reports

The Chinese version of hospital anxiety and depression scale: Psychometric properties in Chinese cancer patients and their family caregivers

(2016) Qiuping Li et al.   European Journal of Oncology Nursing

The Mental Health of People Living with HIV in China, 1998–2014: A Systematic Review

(2016) Lu Niu et al.   PLoS One

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy

(2015) Nathan Ford et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efavirenz and the CNS: what we already know and questions that need to be answered

(2015) Nadezda Apostolova et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

(2015)   LANCET INFECTIOUS DISEASES

Safety of efavirenz in the first trimester of pregnancy

(2014) Nathan Ford et al.   AIDS

Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): A systematic review

(2014) Keira Lowther et al.   INTERNATIONAL JOURNAL OF NURSING STUDIES

Neuronal Bioenergetics and Acute Mitochondrial Dysfunction: A Clue to Understanding the Central Nervous System Side Effects of Efavirenz

(2014) Haryes A. Funes et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

(2014)   LANCET

Stepped-Dose Versus Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events

(2013) Alicia Gutiérrez-Valencia   ANNALS OF INTERNAL MEDICINE

Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis

(2013) Prinitha Pillay et al.   PLoS One

HIV and Depression – a systematic review of interventions

(2011) Lorraine Sherr et al.   Psychology Health & Medicine

A systematic review of Interventions for anxiety in people with HIV

(2011) Claudine Clucas et al.   Psychology Health & Medicine

Relationship between Obstructive Sleep Apnea Severity and Sleep, Depression and Anxiety Symptoms in Newly-Diagnosed Patients

(2010) Paul M. Macey et al.   PLoS One

The mental health of people living with HIV/AIDS in Africa: a systematic review

(2009) René Brandt   AJAR-African Journal of AIDS Research